UPC Analytics
ENDE
Overview · Filed: Aug 14, 2024

UPC_CFI_476/2024

RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

RevocationMain Revocation ActionMilan CDRevocationCase ClosedSettled at: Pre-merits
OverviewDecisionsCitationsDocumentsTimeline
Parties

Claimants

  • Pfizer, Inc.
  • Pfizer Europe MA EEIG
  • Pfizer B.V.
  • Pfizer S.A.
  • Pfizer Manufacturing Belgium S.A.
  • Pfizer Service Company S.R.L.
  • Pfizer Pharma GmbH
  • Pfizer Ltd
Reps: Gareth Williams

Respondents

  • GlaxoSmithKline Biologicals SA
Reps: Oliver Jan Juengst; Daniela Kinkeldey
Judges
  • Andrea Postiglione
  • Anna-Lena Klein
  • Steen Lyders Wadskov-Hansen
Patents
  • EP4183412
  • EP 4 183 412
CPC codes: C12N2760/18522, C12N2760/18534, A61K2039/55505, A61K2039/5258, A61K2039/55566, A61K39/155, A61K39/12, C07K2319/73, A61K2039/53, C07K2317/76, A61P31/14, A61P37/04…

Technology area: Biotech · Vaccines

Sector: Biotechnology

Outcome
WithdrawnWithdrawn
Filed: Aug 14, 2024
First decided: —
Language: English
Settled at: Pre-merits

Milan Central Division allowed Pfizer's withdrawal of the revocation action and the counterclaim for revocation concerning GlaxoSmithKline's EP 4 183 412 (RSV vaccine patent), allowing GSK to withdraw its corresponding patent amendment application. Proceedings were declared closed. Each party bears its own costs. The request for 60% court fee reimbursement was allowed.

Open on UPC Registry